This federal contract award is for the purchase of one (1) Illumina NextSeq 2000 sequencing system and a 12-month service plan by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $390,644 firm fixed-price contract was awarded to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is a base plus one (1) option period, with a final completion date of September 12, 2026. This procurement was not set aside for any specific business size or socioeconomic category. The contract supports NIAID's Vaccine Research Center and Vaccine Immunology Program, which conduct critical research on immunogens, pathogen-specific antibodies, and T-cell responses for vaccines targeting infectious diseases like HIV, influenza, RSV, and COVID-19.